⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 6, 2024Journal of Medical EconomicsOpen Access

Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States

Songkai Yan Cheryl McDade Kris Thiruvillakkat Robert W. Rouse Krupa Sivamurthy Michele Wilson

View Full Paper

Ask AI

Bookmark

Share

Abstract

Introduction: Etranacogene dezaparvovec (EDZ), HemgenixⓇ,is a gene therapy recently approved for people with hemophilia B (PwHB).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yan et al. (2024) studied this question.

synapsesocial.com/papers/68e6b5efb6db643587636cff https://doi.org/10.1080/13696998.2024.2351762

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Assessing health plan payer’s budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States2024
2Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B2025 · 23 citations
3Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in SwedenLate-Phase Clinical Trial · 2026
4Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany2024 · 9 citations
5End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years2025